Swiss Software Stock News

Naturenergie holding AG recently reported its 2025 results, with EBIT of €214 million, higher annual profit, and gross investments of €174 million focused on system-relevant infrastructure, renewable generation, and customer-focused energy solutions, while also declaring an annual dividend of CHF 0.9000 per share payable on May 4, 2026. The company signalled that 2026 EBIT could fall to around €120 million due to weaker marketing prices and regulatory pressures, yet it still plans to lift...

SFS Group (SWX:SFSN) has just posted its FY 2025 numbers, reporting first half revenue of CHF 1.6b and basic EPS of CHF 2.86. This provides an early indication of how the rest of the year might shape investor expectations. The company has reported revenue of CHF 1.56b in the first half of 2024, CHF 1.50b in the second half of 2024, and CHF 1.55b in the first half of 2025. Over the same periods, basic EPS was CHF 3.00, then CHF 3.21, and then CHF 2.86, giving a clear view of how the top line...

mobilezone holding ag (SWX:MOZN) has put fresh numbers on the table for FY 2025, with first half revenue of CHF 429.6 million and EPS of CHF 0.41 setting the tone for the year. The company has seen revenue move from CHF 476.1 million and EPS of CHF 0.44 in the first half of 2024 to CHF 525.3 million and EPS of CHF 0.0757 in the second half, before landing at the current run rate that feeds into trailing 12 month revenue of CHF 958.3 million and EPS of CHF 0.3618. With trailing net margins...

SIG Group AG has released its full-year 2025 results, reporting sales of €3,248.7 million versus €3,328.5 million a year earlier and moving from net income of €194.5 million to a net loss of €87 million. The swing from earnings per share of €0.51 to a basic and diluted loss per share of €0.23 highlights a sharp deterioration in profitability that may prompt investors to reassess the company’s earnings outlook. We’ll now examine how this move from profit to net loss in 2025 could reshape SIG...

Cicor Technologies (SWX:CICN) has reported H1 2025 revenue of CHF 280.7 million and basic EPS of CHF 1.93, setting the stage after a year in which earnings grew 49.7% and net profit margin moved from 3.8% to 4.5%. Over the past three reported halves, revenue has moved from CHF 231.3 million in H1 2024 to CHF 249.5 million in H2 2024 and now CHF 280.7 million in H1 2025, while basic EPS shifted from CHF 2.69 to CHF 3.52 and then CHF 1.93, with margins now doing more of the heavy lifting in the...

Comet Holding (SWX:COTN) has reported its FY 2025 first half results with revenue of CHF 227.2 million and EPS of CHF 1.01, while the trailing twelve months show revenue of CHF 483.2 million and EPS of CHF 5.02 based on the data provided. The company has seen revenue move from CHF 189.3 million and EPS of CHF 0.52 in the first half of 2024 to CHF 256.0 million and EPS of CHF 4.02 in the second half of 2024, setting up FY 2025 against a backdrop of improving net margins and profitability that...

ALSO Holding (SWX:ALSN) has announced a new €120 million share buyback program, targeting up to 9.74% of its share capital for treasury use, acquisitions, liquidity, and management incentives. See our latest analysis for ALSO Holding. The buyback news comes after a weak patch for the shares, with a 30 day share price return showing a decline of 16.53% and a year to date share price return showing a decline of 23.16%. The 1 year total shareholder return shows a decline of 37.67%, which...

If you are wondering whether Swisscom is still reasonably priced after its recent run, you are not alone. This article will help you frame that question clearly. Swisscom's share price closed at CHF 718.0, with returns of 8.5% over 30 days, 24.0% year to date and 44.1% over 1 year. The 7 day return of a 0.5% decline shows that the ride has not been entirely one way. Recent coverage around Swisscom has focused on its role as a major Swiss telecom operator, including ongoing attention on its...

Bossard Holding (SWX:BOSN) FY 2025 Results Set the Tone for Margins and Growth Expectations Bossard Holding (SWX:BOSN) opened FY 2025 with first half revenue of CHF547.9 million and net income of CHF37.4 million, setting a clear earnings benchmark for investors watching how profits track through the rest of the year. The company reported revenue of CHF509.4 million and net income of CHF41.3 million in the first half of 2024, followed by CHF477.0 million and CHF31.1 million in the second half...

Latest FY 2025 headline numbers V-ZUG Holding (SWX:VZUG) has opened FY 2025 with first half revenue of CHF 271.2 million and basic EPS of CHF 0.25, setting a cautious tone around profitability and growth. The company has seen revenue move from CHF 284.1 million in 1H 2024 to CHF 307.6 million in 2H 2024, with EPS shifting from CHF 1.36 to CHF 1.97 over the same periods, before settling at CHF 0.25 in the latest half. This leaves investors focused squarely on how margins are holding up through...

Idorsia reports recent commercial traction for its insomnia drug Quvivic, including broader public reimbursement across major European and North American markets. The company highlights plans for further international rollout of Quvivic and updates on late stage pipeline assets, including pediatric studies. Partnered programs are progressing clinically, with collaborations moving forward alongside Idorsia’s own R&D efforts. Idorsia (SWX:IDIA) is drawing attention as it updates investors on...

European Medicines Agency’s CHMP issues a positive opinion on remibrutinib for adults with chronic spontaneous urticaria who do not respond adequately to standard therapies. CHMP recommendation is based on clinical trial data and represents a key regulatory step for SWX:NOVN in allergic and immunological conditions. Novartis announces plans for a new radioligand therapy manufacturing site in Texas to support production of cancer therapies in the US. Novartis, traded as SWX:NOVN, is a large...

If you are wondering whether Sandoz Group is still attractively priced after its recent run, this article will help you size up what you are really paying for each Swiss franc of the business. The shares closed at CHF64.66, with a 7.0% return over the last month, a 13.0% return year to date, and a 71.1% return over the past year, although the last 7 days saw an 8.1% decline that may have changed how some investors view the risk and reward trade off. Recent news flow around Sandoz Group has...

Galderma Group (SWX:GALD) reports full year sales above $5b, marking a milestone for its dermatology focused portfolio. The company highlights new product launches it describes as having blockbuster potential across its prescription and aesthetics segments. Fresh clinical data show Nemluvio delivering long term efficacy and safety in prurigo nodularis, an area of high unmet medical need. Regulatory approval of new device technology supports further expansion of Galderma's aesthetics...

Amrize (SWX:AMRZ) has introduced its new EVERtect™ high-performance concrete range for customers in North America. The portfolio includes multiple specialized mixes tailored for different construction uses across the U.S. and Canada. The launch expands Amrize’s presence in high-spec concrete solutions for both structural and low-carbon applications. For you as an investor, this move highlights how Amrize is positioning its core materials business around more differentiated, higher-spec...

If you are wondering whether ABB's current share price still makes sense after a strong run, this article breaks down what you are really paying for the business today. ABB shares last closed at CHF 67.20, with returns of 46.1% over 1 year and 181.5% over 5 years. The shorter term picture is mixed, with a 4.8% decline over 7 days but a 9.7% gain year to date. Recent headlines have focused on ABB's ongoing position as a major player in electrification and automation, as well as its exposure...

Alcon reports that more than 175 million of its intraocular lenses have been implanted worldwide. The milestone highlights broad adoption of the company’s presbyopia-correcting IOLs across global eye care practices. Alcon plans further intraocular lens launches, subject to regulatory approvals. For investors following Alcon (SWX:ALC), this update comes with the shares trading at CHF63.96 and a value score of 4. The stock shows a 22.3% decline over the past year, while 3-year and 5-year...

On 24 February 2026, Iconovo AB announced it had signed a Letter of Intent with Lonza Group to pursue a long-term collaboration around spray dried formulation capabilities for inhalable biologics, building on their existing work on an obesity project. This potential alliance links Lonza’s CDMO scale with Iconovo’s five-platform inhaler technology targeting biologics and high-value respiratory franchises with global turnover of about US$9.00 billion. We’ll now examine how this focus on spray...

Avolta AG recently completed the cancellation of about 4.9 million treasury shares, reducing its registered share capital to CHF 708,241,695 across 141,648,339 shares, while continuing to expand its food and beverage footprint at key airports in Italy and Canada. This combination of a tighter share base and integrated travel retail and dining growth highlights Avolta’s focus on capital efficiency alongside strengthening its airport partner relationships. Next, we’ll examine how Avolta’s...

Zurich Insurance Group has confirmed the acquisition of UK based insurer Beazley, following completion of an accelerated equity offering to fund the deal. The transaction expands Zurich's presence in international insurance markets and follows investor backing via fresh equity capital. The company, trading as SWX:ZURN, remains in focus as integration plans and capital impacts come into view for shareholders. Zurich Insurance Group, ticker SWX:ZURN, is approaching this deal with a current...

Sandoz Group (SWX:SDZ) has received EU marketing authorization for Ranluspec. The approval expands the company’s biosimilars portfolio into the ophthalmology segment. The decision supports an expected product launch later in 2026 across European markets. For you as an investor, this represents a business development in a high-value area of medicine. Sandoz focuses on biosimilars and generics, and Ranluspec adds another product aimed at chronic eye conditions where long-term treatment is...

Why the infant formula recalls matter for Nestlé (SWX:NESN) Nestlé (SWX:NESN) is under close watch after recalling infant formula products in more than 60 countries due to low levels of the cereulide toxin, prompting tighter safety controls and raising fresh questions for shareholders about risk and resilience. See our latest analysis for Nestlé. Despite concerns around the recalls, Nestlé’s recent 30 day share price return of 13.32% and year to date share price return of 8.86% contrast with...

Recent commentary around rapid growth in digital mining, particularly for lithium and copper related to electric vehicles and the energy transition, has put ABB (SWX:ABBN) in focus as it expands partnerships and mining technologies. See our latest analysis for ABB. Against this backdrop of digital mining partnerships and technology deployments, ABB’s share price sits at CHF70.64, with a 90 day share price return of 22.98% and a 1 year total shareholder return of 47.76%. This suggests momentum...

dormakaba Holding (SWX:DOKA) moved into focus after its H1 2026 results, reporting sales of CHF 1,362.7 million and net income of CHF 40.5 million, both below the prior half year. See our latest analysis for dormakaba Holding. The H1 2026 earnings release helps explain why the 90 day share price return sits at a decline of 13.01%, even though the 3 year total shareholder return is a gain of 41.09% and recent momentum has weakened despite a 3.60% 1 day share price return to CHF57.5. If this...